All news - Pipelinereview
网页2 天之前 · LEHI, UT, USA I September 23, 2024 I Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced promising preclinical results from their investigational compound HT-6184, combined with the GLP-1 agonist semaglutide. The study revealed significant weight loss in a diet-induced obesity (DIO) mouse ...
PipelineReview.com. Biopharmaceutical News & Clinical Trials
网页PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email info@lamerie.com
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN …
网页2021年3月2日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Siamab Therapeutics and Boehringer Ingelheim Announce …
网页NEWTON, MA, USA I October 4, 2017 I Siamab Therapeutics, Inc. and Boehringer Ingelheim announced today that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor associated carbohydrate antigens (TACAs). Siamab will apply its proprietary technology platform to generate TACA-specific antibodies for use in multiple solid ...
Furiex Pharmaceuticals Announces Positive Top-Line Results of …
网页2014年2月4日 · MORRISVILLE, NC, USA I February 4, 2004 I Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency ...
AbbVie and FutureGen Announce License Agreement to Develop …
网页2024年6月13日 · – Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, IL, USA and BEIJING, China I June 13, 2024 I AbbVie (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. today announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently ...
Transaction includes actinium-based clinical-stage radioconjugate ...
网页2024年3月19日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
FibroGen Announces Topline Results from Phase 1 ... - Pipelinereview
网页2024年4月3日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
FDA grants Carmell Therapeutics Expedited Review for CT-101, …
网页2020年4月27日 · Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment. PITTSBURGH, PA, USA I April 27, 2020 ICarmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, announced that ...
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 ...
网页2021年9月4日 · BASEL, Switzerland I September 03, 2021 I Novartis today announced that following an interim analysis of data from the CIRRUS-1 study, a decision has been taken to discontinue the trial.. The analysis indicated that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant.
跳至内容